The CMTA is a global leader in the acceleration of CMT research and pre-clinical testing. The CMTA will be attending the BIO annual meeting in Boston and have availability for partner meetings from Monday June 5 through Wednesday June 7.
Mark Scheideler, Alliance Partner Lead, will be attending the conference and is setting up meetings to explore alliance relationships. The CMTA has been very active in partnering preclinical services, as a means of enabling companies to explore a CMT therapy indication with a highly validated testing platform.
Details of the service are posted on the CMTA website: mark@hftherapeutics.com to share your needs and book a meeting slot. We’re keen to explore collaboration, answer research questions and discuss pre-clinical testing needs with biotech and pharma groups, academic labs and patient advocacy partners.
Mark’s profile and work with the CMTA can be viewed at https://www.linkedin.com/in/markscheideler.
Published: May 10, 2023